论文部分内容阅读
目的探讨抗病毒治疗妊娠晚期乙型肝炎在阻断乙肝病毒(HBV)母婴传播中的效果。方法选取2015年10月-2016年7月在庆阳市人民医院接受治疗的84例乙肝表面抗原(HBsAg)阳性的妊娠晚期孕妇为研究对象,按随机数表法分为对照组(42例)和研究组(42例)。对照组患者采用被动免疫方法治疗,研究组患者在对照组治疗基础上联合采用核苷类抗病毒药物治疗。比较两组孕妇在治疗前后HBV-DNA定量、HBVe抗原(HBeAg)水平及婴儿12个月时的HBV-DNA定量、HBeAg阳性率。结果和治疗前比较,治疗后两组孕妇的HBV-DNA定量、HBeAg水平均明显下降,且研究组下降幅度更大(P<0.05);出生12个月时,研究组婴儿的HBV-DNA定量检测、HBeAg阳性率均明显低于对照组(P<0.05)。结论对妊娠晚期乙型肝炎患者采用核苷类抗病毒药物治疗可有效阻断HBV母婴传播,提高免疫成功率,促进患者身体恢复。
Objective To investigate the effect of antiviral treatment of hepatitis B in late pregnancy on the block of mother-to-child transmission of hepatitis B virus (HBV). Methods Eighty-four pregnant women with HBsAg positive during the period from October 2015 to July 2016 in Qingyang People’s Hospital were divided into control group (n = 42), randomized controlled clinical trial And study group (42 cases). Patients in the control group were treated with passive immunization. Patients in the study group were treated with nucleoside antiviral drugs on the basis of the control group. HBV-DNA, HBVe antigen (HBeAg) levels and HBV-DNA quantitation and HBeAg positive rate at 12 months were compared between the two groups before and after treatment. Results Compared with those before treatment, the levels of HBV-DNA and HBeAg in both groups were significantly decreased after treatment, and the decrease in the study group was greater (P <0.05). At 12 months of birth, the HBV-DNA in the study group The positive rate of HBeAg was significantly lower than that of the control group (P <0.05). Conclusion The treatment of hepatitis B virus in patients with late pregnancy with nucleoside antiviral therapy can effectively block the transmission of HBV from mother to infant, improve the success rate of immunization and promote the recovery of patients.